BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29569824)

  • 1. Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy.
    Mmeje CO; Benson CR; Nogueras-González GM; Jayaratna IS; Gao J; Siefker-Radtke AO; Kamat AM; Dinney CP; Navai N; Shah JB
    BJU Int; 2018 Jul; 122(1):89-98. PubMed ID: 29569824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study.
    Gandaglia G; Popa I; Abdollah F; Schiffmann J; Shariat SF; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI; Sun M
    Eur Urol; 2014 Sep; 66(3):561-8. PubMed ID: 24486024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity.
    Johnson DC; Nielsen ME; Matthews J; Woods ME; Wallen EM; Pruthi RS; Milowsky MI; Smith AB
    BJU Int; 2014 Aug; 114(2):221-8. PubMed ID: 24274722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomy.
    Arora A; Zugail AS; Pugliesi F; Cathelineau X; Macek P; Barbé Y; Karnes RJ; Ahmed M; Di Trapani E; Soria F; Alvarez-Maestro M; Montorsi F; Briganti A; Necchi A; Pradere B; D'Andrea D; Krajewski W; Roumiguié M; Bajeot AS; Hurle R; Contieri R; Carando R; Teoh JY; Roupret M; Benamran D; Ploussard G; Mir MC; Sanchez-Salas R; Moschini M
    World J Urol; 2022 Jul; 40(7):1697-1705. PubMed ID: 35488914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to improve patient selection for neoadjuvant chemotherapy in bladder cancer patients candidate for radical cystectomy and pelvic lymph node dissection.
    Zamboni S; Moschini M; Antonelli A; Simeone C; Belotti S; Cristinelli L; Montorsi F; Briganti A; Gallina A; Salonia A; Colombo R; Mordasini L; Mattei A; Baumeister P
    World J Urol; 2020 May; 38(5):1229-1233. PubMed ID: 31463561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy.
    Zargar-Shoshtari K; Zargar H; Dinney CP; Ercole CE; Sharma P; Kovac E; Grivas PD; Stephenson AJ; Shah JB; Black PC; Spiess PE
    World J Urol; 2016 May; 34(5):695-701. PubMed ID: 26286880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience.
    Abdelrahman I; Aboulkassem H; Elazab A; Abdallah AY; Ismail Y; Taher M
    J Egypt Natl Canc Inst; 2023 May; 35(1):13. PubMed ID: 37145329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder.
    Hensley PJ; Goodwin J; Davenport DL; Strup SE; James A
    Clin Genitourin Cancer; 2018 Aug; 16(4):e851-e858. PubMed ID: 29548614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
    Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
    Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Chemotherapy Does Not Increase the Morbidity of Radical Cystectomy: A 10-year Retrospective Nationwide Study.
    Salminen AP; Koskinen I; Perez IM; Hurme S; Murtola TJ; Vaarala MH; Nykopp TK; Seppänen M; Isotalo T; Marttila T; Levomäki L; Becker S; Anttinen M; Liukkonen T; Säily M; Pogodin-Hannolainen D; Viitanen J; Palmberg C; Ottelin J; Sairanen J; Ettala OO; Boström PJ
    Eur Urol Oncol; 2018 Dec; 1(6):525-530. PubMed ID: 31158099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging.
    Audenet F; Sfakianos JP; Waingankar N; Ruel NH; Galsky MD; Yuh BE; Gin GE
    Urol Oncol; 2019 Feb; 37(2):116-122. PubMed ID: 30509868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of suboptimal neoadjuvant chemotherapy on peri-operative outcomes and survival after robot-assisted radical cystectomy: a multicentre multinational study.
    Hinata N; Hussein AA; George S; Trump DL; Levine EG; Omar K; Dasgupta P; Khan MS; Hosseini A; Wiklund P; Guru KA
    BJU Int; 2017 Apr; 119(4):605-611. PubMed ID: 27743481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes.
    Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
    Eur Urol Oncol; 2019 Jul; 2(4):390-396. PubMed ID: 31277775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy.
    Regnier P; DE Luca V; Brunelle S; Sfumato P; Walz J; Rybikowski S; Maubon T; Branger N; Fakhfakh S; Durand M; Gravis G; Pignot G
    Minerva Urol Nephrol; 2021 Apr; 73(2):215-224. PubMed ID: 32083413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of robot-assisted vs. open radical cystectomy.
    Hanna N; Leow JJ; Sun M; Friedlander DF; Seisen T; Abdollah F; Lipsitz SR; Menon M; Kibel AS; Bellmunt J; Choueiri TK; Trinh QD
    Urol Oncol; 2018 Mar; 36(3):88.e1-88.e9. PubMed ID: 29277584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.
    Mertens LS; Meijer RP; Meinhardt W; van der Poel HG; Bex A; Kerst JM; van der Heijden MS; Bergman AM; Horenblas S; van Rhijn BW
    BJU Int; 2014 Jul; 114(1):67-74. PubMed ID: 24053889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
    Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
    Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy.
    Milenkovic U; Akand M; Moris L; Demaegd L; Muilwijk T; Bekhuis Y; Laenen A; Van Cleynenbreugel B; Everaerts W; Van Poppel H; Dumez H; Albersen M; Joniau S
    World J Urol; 2019 Sep; 37(9):1857-1866. PubMed ID: 30519746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy.
    Chalfin HJ; Liu JJ; Gandhi N; Feng Z; Johnson D; Netto GJ; Drake CG; Hahn NM; Schoenberg MP; Trock BJ; Scott AV; Frank SM; Bivalacqua TJ
    Ann Surg Oncol; 2016 Aug; 23(8):2715-22. PubMed ID: 27012987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA.
    Hanna N; Trinh QD; Seisen T; Vetterlein MW; Sammon J; Preston MA; Lipsitz SR; Bellmunt J; Menon M; Choueiri TK; Abdollah F
    Eur Urol Oncol; 2018 May; 1(1):83-90. PubMed ID: 31100232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.